A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumors Clinical Trial

Official title:

A Phase I/II Clinical Study of Avapritinib in Chinese Subjects With Unresectable or Metastatic Gastrointestinal Stromal Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04254939
• Other study ID #: CS3007-101
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: August 15, 2019
• Est. completion date: April 11, 2023

Study information

• Verified date: April 2023
• Source: CStone Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open-label, multicenter, phase I/II study to evaluate the safety, PK and clinical efficacy of avapritinib in Chinese subjects with unresectable or metastatic GIST. The study consists of two parts: dose escalation (phase I) and dose expansion (phase II).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: April 11, 2023
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

1. For phase I study, the subject must have histologically or cytologically confirmed unresectable or metastatic GIST that progressed after imatinib and at least one additional TKI treatment, or who cannot tolerate the standard treatment or have D842V mutation in the PDGFRa gene.

2. For phase II study:

i) Group 1: Chinese subjects with unresectable GIST harboring D842V mutation in PDGFRa gene.

ii) Group 2: Chinese third-line and fourth-line or later subjects with unresectable GIST that has progressed after standard treatment and/or do not tolerate standard treatment, and do not have a known D842V mutation in the PDGFRa gene.

3. Subjects with at least one measurable lesion as defined per mRECIST v1.1

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Exclusion Criteria

1. Subject has any of the laboratory results that meet exclusion criteria

2. Subjects who have previously received antineoplastic medication, including Chinese herbal drugs or Chinese medicine products with antineoplastic indications, for less than 5 half-lives or 14 days, whichever is shorter, prior to the first dose of the investigational product.

3. The subject received neutrophil growth factor support within 14 days prior to the first dose of investigational product.

4. Subjects received treatment with a strong inhibitor or strong or moderate inducer of cytochrome P450 (CYP) 3A4 within 14 days prior to the first dose of study drug, or requires continuous intake of above medications or foods during study period.

5. Subject received a major surgery (not including minor procedures, e.g., central venous catheterization, tumor needle biopsy, feeding tube placement) within 14 days prior to the first dose of investigational product.

6. Diagnosis of any other malignancy within 1 year prior to the first dose of investigational product or the subject is under treatment for another malignancy.

7. Corrected QT interval > 450 msec calculated using Fridericia's formula.

8. Subject has history of seizure (e.g. epilepsy) or requires antiepileptic medication treatment.

9. History of cerebrovascular accident or transient ischemic attack within one year prior to the first dose of the investigational product.

10. Known risk of intracranial hemorrhage, e.g., history of cerebral aneurysm or subdural or subarachnoid hemorrhage.

11. With primary brain malignancy or brain metastasis.

12. With clinically significant, uncontrolled cardiovascular disease, including congestive heart failure of New York Heart Association (NYHA) class II, III or IV, myocardial infarction or unstable angina in the past 6 months, or uncontrolled hypertension.

13. Unwilling or unable to comply with scheduled visits, treatment plan, laboratory tests or other study procedures/restrictions.

14. With previous or current clinically significant disorder, medical condition, history of surgery, physical issue or laboratory finding, which, in the investigator's judgment, might affect the subject's safety, change the absorption, distribution, metabolism or excretion of the investigational product, or interfere with the evaluation of study result.

Related Conditions & MeSH terms

• Gastrointestinal Stromal Tumors

Intervention

Drug:
• CS3007 (BLU-285)
A modified "3+3" dose escalation design will be adopted. Each group will enroll 3-6 subjects. Avapritinib will be administered orally at the starting of 200 mg QD. A cycle consists of 28 consecutive days.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing
China	Chinese PLA General Hospital	Beijing	Beijing
China	The First Affiliated Hospital of Chongqing Medical University	Chongqing	Chongqing
China	Fujian Medical University Union Hospital	Fuzhou	Fujian
China	The First Affiliated Hospital of Sun Yat-Sen University	Guangzhou	Guangdong
China	The Sixth Affiliated Hospital of Sun Yat-Sen University	Guangzhou	Guangdong
China	The First Affiliated Hospital Zhe Jiang University	Hangzhou	Zhejiang
China	Harbin Medical University Cancer Hospital	Harbin	Heilongjiang
China	The First Affiliated Hospital of Nanchang Medical University	Nanchang	Jiangxi
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai
China	Fudan University Zhongshan Hospital (General Surgery Department)	Shanghai	Shanghai
China	Fudan University Zhongshan Hospital (Internal Tumor Department)	Shanghai	Shanghai
China	Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Liaoning Cancer Hospital & Institute	Shenyang	Liaoning
China	Xinjiang Medical University Cancer Hospital	Urumqi	Xinjiang
China	Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (2)

Lead Sponsor	Collaborator
CStone Pharmaceuticals	Blueprint Medicines Corporation

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Recommended Phase II dose (RP2D), incidence of dose limiting toxicities (DLT) in Cycle 1, incidence and severity of adverse events and serious adverse events and changes in vital signs, clinical laboratory results and ECG findings		at the end of Cycle 1 (each cycle is 28 days) for RP2D and DLT; during every cycle through 30 days after the last dose of study drug, an average of approximately 24 months, for other measures
Primary	Phase II: ORR based on mRESIST 1.1		At Cycle 3 (each cycle is 28 days) Day 1, then every 2 cycles until Cycle 13, they every 3 cycles through study completion, disease progression or patient discontinuation from the study (whichever comes first), an average of approximately 24 months